Back to search results

18F-rhPSMA-7.3 for Prostate Cancer After Focal Treatment

This study is looking at how well a special scan, called a PSMA-PET scan, can find prostate cancer that has come back after a treatment called focal gland therapy. We are testing a substance called 18F-rhPSMA-7.3, which helps the PSMA-PET scan work. PSMA is a protein often found on prostate cancer cells, making it a good target for imaging. This study aims to see if these scans can help doctors understand the location and extent of prostate cancer after focal therapy. You may be able to join if you are an adult male, 18 years or older, who has had an MRI before treatment and underwent focal or hemiablation for intermediate-risk prostate cancer within the last 9 months. The study will measure how effective the PSMA-PET scan is about one year after your focal therapy. The current status of this study is unclear.

Study design
This is an interventional study with a planned enrollment of 70 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be evaluated approximately 1 year after their standard of care (SOC) focal therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07011342

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

Recruiting
NAAges 18+InterventionalDiagnostic
Hackensack Meridian Health
~70 participants
Updated 2026-03-23 on ClinicalTrials.gov
What's tested:18F-rhPSMA-7.3

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate the effectiveness of PSMA-PET scan in identifying recurrent prostate cancer after focal therapy
Measured over Approximately 1 year after SOC focal therapy.

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
New Jersey1

Study leadership

  • Nitin Yerrman, MD · PRINCIPAL_INVESTIGATOR · Hackensack Meridian Health

Who to contact

Oncology Clinical Research Referral Office
[email protected]
551-996-1777
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult males 18 years or older;
Patient must have a pre-treatment MRI;
Patient underwent SOC focal therapy with either focal or hemiablation for the treatment of intermediate risk prostate cancer in the past 9 months prior to enrollment;
Intermediate risk disease as defined by American Urology Academy (AUA)/National Comprehensive Cancer Network (NCCN) guidelines (see Appendix A)
Life Expectancy of 10 years or more;
Underwent standard template biopsy before treatment with a minimum of 2 cores into the MRI visible lesion if lesion was present;
Patient understands the purpose of the trial and procedures required for the trial, and can provide signed informed consent as which includes compliances with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol; and
Ability to adhere to the study visit schedule and all the protocol requirements, including surveillance imaging and test specimen (blood sample) collection at specified time points.

Exclusion

Patients under the age of 18 will be considered pediatric patients and will not be included in this study because they are thought to represent a unique population outside the scope of this study as it is aimed at identifying factors that affect adults only.
Patients previously treated with whole gland ablation or prior partial gland ablation over 9 months prior to enrollment.

What this trial measures

  • To evaluate the effectiveness of PSMA-PET scan in identifying recurrent prostate cancer after focal therapyApproximately 1 year after SOC focal therapy.

    All patients will get a biopsy to assess the effectiveness of treatment at 1 year, which is standard protocol at our institutions (all patients undergo biopsy at year 1 and 3 at our institutions). The post-treatment PSMA-PET scan will be correlated to 1-year biopsy results to study the utility of such a scan. Recurrence is defined by a positive PSMA-PET scan and positive biopsy in the area of PET scan tracer uptake at 1 year after SOC focal treatment.